Guidance Notes and Best Practice Guides
BHF: New physical activity guidelines for the UK include specific guidance for under-fives for the first time. Released by the UK’s chief medical officers, they state that pre-school children who are able to walk should be active for at least 3 hours a day, though this doesn't need to be in one go.
ScotGov: A code of practice is being drawn up to help the increasing numbers of new residents who are moving into Scotland's towns & cities to get on well with their neighbours. But the influx of 4-legged visitors aren't coming from overseas - Scotland's urban areas are now home to increasing numbers of roe deer.
A Scotland-wide Deer Code is also being developed to address issues such as:
* Road accidents caused by deer
* Wildlife crime, including deer coursing & poaching
* Welfare
DH: New advice as to how people of all ages can maintain fitness levels and stay or get healthy, has been launched as part of the first UK-wide physical activity guidelines by the 4 nations’ Chief Medical Officers. A key new element is a more flexible approach for adults to get their 150 minutes of activity a week.
The guidelines build on previous advice, but reflect the growing body of knowledge about physical activity levels and links to reducing the risk of serious diseases like heart disease, stroke & diabetes.
The guidelines build on previous advice, but reflect the growing body of knowledge about physical activity levels and links to reducing the risk of serious diseases like heart disease, stroke & diabetes.
ScotGov: A guide on how to ensure local services are better designed & built around people & local communities has been launched by the Scottish Government. The guidance (Public Social Partnership Guidance 2011) builds on the experience of 10 projects, in a range of areas including social care, youth services & recycling. These piloted new ways to effectively link the public & third sectors and to ensure the people & communities are kept at the centre of all discussions on the design & management of the service.
NICE: In final draft guidance, NICE has NOT recommended ranibizumab (Lucentis, Novartis) for the treatment of diabetic macular oedema (DMO).
